OHSU in the news

Health care giant Optum faces new scrutiny after fumbled arrival in Eugene, but it’s already entrenched in Oregon

The Oregonian May 16, 2024
In an Oregonian/Oregonlive article about Optum’s takeover of the Oregon Medical Group and other practices, Jane Zhu, M.D., says federal regulation and most state laws do not require corporations and private equity firms to publicly disclose most mergers and acquisitions. “That adds a layer of opaqueness to understanding who owns what in health care,” Zhu says.

SEQUOIA-HCM Trial: Experimental Drug Aficamten Makes Exercise, Everyday Tasks Easier for People With Obstructive Hypertrophic Cardiomyopathy

Cath Lab Digest May 14, 2024
OHSU is participating in an international clinical trial involving a new drug for hypertrophic cardiomyopathy. Results recently published in the New England Journal of Medicine reveal the drug successfully increases oxygen use during exercise, making everyday tasks easier for people with hypertrophic cardiomyopathy. Ahmad Masri, M.D., says: “By having more oxygen available during exercise, patients with obstructive hypertrophic cardiomyopathy can more easily walk, perform household chores, and do other everyday tasks.”

OHSU doctor says rainy weather can help those with asthma

KPTV May 10, 2024
In a KPTV story about an increase in allergy and asthma symptoms as the weather warms, Shyam Joshi, M.D., says rainy weather can be beneficial: “It’s been a little bit wetter, a little bit rainier, which prevents the pollen from really getting into the air kind of knocks it down."

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

The ASCO Post May 10, 2024
An article in the ASCO Post on the phase III COMPASSION-15 trial, which is investigating a treatment for advanced gastric cancer gastroesophageal junction adenocarcinoma, includes comments from Shivaani Kummar, M.D., who moderated the press conference where trial data were presented. Kummar says: “It is interesting data, especially for patients with a PD-L1 expression level of [combined positive score] < 5. Data would need to be confirmed in additional patient trials before this would be considered standard of care in the United States.”

Gene therapy improves vision in Leber congenital amaurosis patients

Optometry Today May 10, 2024
An OHSU study finds about 79% of clinical trial participants with leber congenital amaurosis experienced measurable improvement after receiving experimental, CRISPR-based gene editing: “This [is] a blinding disease with no treatments ... an enormous burden on patients [due] to their vision loss,” says Mark Pennesi, M.D., Ph.D.

Calls to poison centers for fentanyl exposure in kids increased nearly 54-fold since 2016

ABC News May 10, 2024
Calls to poison centers, including the Oregon Poison Center at OHSU, for illicit fentanyl exposures in kids younger than 6 increased from 10 cases in 2016 to 539 in 2023. Rob Hendrickson, M.D., says: "It is imperative that the community provides resources to end the fentanyl epidemic and that people who use illicit drugs secure them from children by using opaque child-resistant lockable containers. We are extremely concerned about what we are seeing in the community and will continue to bring the issue to the forefront to raise awareness about how to prevent unintentional exposures among children."

There’s a New Covid Variant. What Will That Mean for Spring and Summer?

The New York Times May 10, 2024
In a The New York Times article about a new variant called KP.2, Fikadu Taffese, Ph.D., says researchers are still trying to determine to what degree repeat infections raise the risk of developing long COVID, as the pandemic continues to evolve. “That’s the nature of the virus. It keeps mutating," Tafesse says.
See more stories